Zobrazeno 1 - 10
of 157
pro vyhledávání: ''
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 137
Objective Histologic types are correlated with prognosis in lung adenocarcinoma. The acinar/papillary type is most common, although this group comprises heterogeneous tumor types. However, the prognostic factors in this group have not been well studi
Autor:
Yoko Korenaga Fukuda, Jeffrey W. Clark, Shirish M. Gadgeel, Pasi A. Jänne, Patrick M. Forde, Giulia Costanza Leonardi, Sasha Kravets, Viola W. Zhu, Daniel B. Costa, Lynette M. Sholl, Sai-Hong Ignatius Ou, D. Ross Camidge, Rebecca S. Heist, Suzanne E. Dahlberg, Tony Mok, Alexander Drilon, Mark M. Awad, Sinead A. Noonan, Conor E. Steuer
Publikováno v:
Lung Cancer
Objectives Although dramatic responses to MET inhibitors have been reported in patients with MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC), the impact of these treatments on overall survival in this population is unknown. Methods We
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 134
Objectives We evaluated the safety and efficacy of the combination therapy of afatinib, an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and ruxolitinib, a JAK1/2 selective inhibitor, in patients with EGFR muta
Autor:
John R. Goffin, Samantha Gray, Paul Wheatley-Price, Nevin Murray, Charles Butts, Normand Blais, Penelope A. Bradbury, Jenny Ko, Garth Nicholas, P. Brown-Walker, Scott A. Laurie, Marie Florescu, Jeffrey Rothenstein, Pardeep Kaurah, Cynthia Card, M. Neil Reaume, Dongsheng Tu, Leah M. Prentice, Natasha B. Leighl, Lesley Seymour, Hongbo Lui, Barbara Melosky, Anthony Reiman, Naveen S. Basappa, Glenwood D. Goss
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Introduction Activation of the RAS/RAF/MEK/ERK pathway may confer resistance to chemotherapy in non-small cell lung cancer (NSCLC). Selumetinib (AZD6244, ARRY142886), a MEK1/2 inhibitor combined with chemotherapy in patients with NSCLC was evaluated
Autor:
Keunchil Park, Martin Schuler, Yi-Long Wu, Vera Hirsh, Ki Hyeong Lee, Caicun Zhou, Shun Lu, Angela Märten, Stuart H. Ellis, James Chih-Hsin Yang, W. Tang, Luis Paz-Ares, Carl Samuelsen, E. Ehrnrooth, Lecia V. Sequist, Jifeng Feng
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Objectives In patients with advanced epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC), first-line afatinib significantly improved progression-free survival (PFS) and objective response vs. platinum-double
Autor:
Qing Shi, Mu-Chen Zhang, Li Wang, Wei-Li Zhao, Fu-hua Yan, Min Zhou, Shuo Wang, Qi Song, Jieming Qu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 132
Background Pulmonary lymphoma arises primarily from the lung, which is extremely rare, or be secondarily involved by lymphoma. The clinical features, management, and prognostic factors have not been clearly identified. Methods Sixty-three patients wi
Autor:
Sukhmani K. Padda, Joseph B. Shrager, Summer S. Han, Joel W. Neal, Christian A. Kunder, Jacqueline V. Aredo, Heather A. Wakelee
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung cancer (NSCLC) and may differentially influence patient outcomes. We sought to characterize the effects of KRAS mutation subtypes and concurrent pathogenic mutations on ove
Autor:
Kenneth J. O'Byrne, Jaafar Bennouna, Vera Hirsh, Kazuhiko Nakagawa, Eng Huat Tan, Yi-Long Wu, Tony Mok, Shun Lu, Li Zhang, James Chih-Hsin Yang, Martin Schuler, Toyoaki Hida, Hiroshi Tanaka, Terufumi Kato, Keunchil Park, Denis Moro Sibilot, Michael Boyer, Nobuyuki Yamamoto, Angela Märten, Caicun Zhou, W. Tang, Luis Paz-Ares
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 132
Objectives With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in some patients. I
Autor:
Jesper Ravn, Jane Christensen, Torben Riis Rasmussen, Niels Lyhne Christensen, Erik Jakobsen, Susanne Oksbjerg Dalton
Publikováno v:
Christensen, N L, Dalton, S, Ravn, J, Christensen, J, Jakobsen, E & Rasmussen, T R 2019, ' Treatment, no treatment and early death in Danish stage I lung cancer patients ', Lung Cancer, vol. 131, no. May, pp. 1-5 . https://doi.org/10.1016/j.lungcan.2019.03.007
Christensen, N L, Dalton, S, Ravn, J, Christensen, J, Jakobsen, E & Rasmussen, T R 2019, ' Treatment, no treatment and early death in Danish stage I lung cancer patients ', Lung Cancer, vol. 131, pp. 1-5 . https://doi.org/10.1016/j.lungcan.2019.03.007
Christensen, N L, Dalton, S, Ravn, J, Christensen, J, Jakobsen, E & Rasmussen, T R 2019, ' Treatment, no treatment and early death in Danish stage I lung cancer patients ', Lung Cancer, vol. 131, pp. 1-5 . https://doi.org/10.1016/j.lungcan.2019.03.007
Background: Stage I lung cancer is curable with surgery as the treatment of choice. Other effective and curative treatments exist. Nevertheless, some patients only receive palliative treatment and some receive no treatment at all. Materials and metho
Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos
Autor:
Filippo Lococo, Lorenzo Spaggiari, Elisa Dieci, Alessandro Misotti, Pierluigi Novellis, Benedetta Persechino, Luca Fontana, Raffaella Bertolotti, Giulia Veronesi, Patrick Maisonneuve, Cristiano Rampinelli, Monica Casiraghi, Iavicoli S, Michela Solinas, Massimo Bellomi, Marco Alloisio
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 131
Objectives Smoking is the main risk factor for lung cancer, but environmental and occupational exposure to carcinogens also increase lung cancer risk. We assessed whether extending low-dose computed tomography (LDCT) screening to persons with occupat